Despite preventive treatment, HAE patients require on-demand care
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
Sebetralstat Can Ease Abdominal and Peripheral Attacks, Trial Reports
Treatment with sebetralstat, an investigational and oral on-demand therapy, resulted in rapid relief for both abdominal and peripheral attacks in adults with hereditary angioedema (HAE), according to a new analysis Phase 2 trial data. Sebetralstat (formerly KVD900), by KalVista Pharmaceuticals, is a small molecule inhibitor of the…
Phase 3 Trial of KVD900 as Oral, On-demand HAE Therapy Opening
KalVista Pharmaceuticals has launched a Phase 3 trial, called KONFIDENT, to test the safety and effectiveness of KVD900, an experimental oral and on-demand treatment for swelling attacks in people with hereditary angioedema (HAE). “Beginning the KONFIDENT trial represents a major milestone for KalVista,” Andrew Crockett, the company’s…
FDA Puts Hold on KalVista’s Phase 2 Trial of KVD824 for HAE Attacks
The U.S. Food and Drug Administration (FDA) has placed a hold on KalVista Pharmaceuticals’ proposed Phase 2 trial of KVD824 — which the developer had expected to launch by the end of June. The trial is intended to test…
Recent Posts
- Voices for change in a village of rare disease advocates, part 1
- I’ve learned that severe weather and HAE have a lot in common
- Orladeyo reduces swelling rates in severe HAE: Real-world data
- Travel plans for an HAE conference include caution
- Donidalorsen may improve quality of life for people with HAE